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STEVEN C. SALARIS, CHARLES F. BARBS, and WILLIAM D. VOORHEES III 
 
Biomedical Engineering Center, and School of Veterinary Medicine, Purdue University, West 
Lafayette, Indiana, USA. 
 





Tissue oxidases, especially xanthine oxidase, have been proposed as primary sources of toxic 
oxygen radicals in many experimental models of disease states. Among these, ischemia-
reperfusion injury may be of the greatest clinical interest. In this paper we propose the use of 
methylene blue as a means of suppressing the production of superoxide radicals, O2

, by acting 
as an alternative electron acceptor for xanthine oxidase. Previous work has indicated that 
methylene blue accepts electrons from xanthine oxidase at the iron-sulfur center. Initial 
experiments in our laboratory demonstrated that (1) pairs of electrons from each enzymatic 
oxidation are transferred to methylene blue, (2) the reduction of methylene blue can be achieved 
by model iron-sulfur centers, similar to the iron-sulfur center of xanthine oxidase, (3) reduced 
methylene blue auto-oxidizes to produce H2O2 directly, rather than O2

,  and (4) methylene blue 
is effective at non-toxic levels (2-5 mg/kg) in preventing free radical damage to liver and kidney 
tissues in an in vitro model of ischemia and reoxygenation. Accordingly, we propose that 
methylene blue may represent a new class of antioxidant drugs that competitively inhibit 
reduction of molecular oxygen to superoxide by acting as alternative electron acceptors for tissue 
oxidases. We have termed these agents “parasitic” electron acceptors. 
 
Key words: class, drug development, hydrogen peroxide, new, novel, oxidative stress, reactive 
oxygen species, therapy 
 
Abbreviations: DMSA, dimercaptosuccinic acid; HO, hydroxyl radical; HX, hypoxanthine; 
LD50, median lethal dose; MDA-LM, malondialdehyde-like materials; NBT, nitroblue 
tetrazolium; SOD, superoxide dismutase; and X, xanthine. 
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An increasing body of evidence implicates the involvement of oxygen-derived free radicals in 
the pathophysiology of arthritis, iron toxicity, Parkinson’s disease, and a variety of disease states 
including ischemia followed by reperfusion [l-4]. Superoxide (O2

) is undoubtedly the most 
abundant oxygen radical generated in vivo. Biological sources of superoxide include activated 
leukocytes [5], the mitochondrial electron transport chain [6], and tissue oxidases, most notably 
xanthine oxidase [7-9]. The current model of reperfusion injury [l, 7, 10, 11] states that during 
the ischemic period, hypoxanthine and xanthine substrates accumulate due to the anaerobic 
breakdown of ATP. At the same time, there is a measurable increase in the amount of xanthine 
oxidase in the cell due to a proteolytic conversion of xanthine dehydrogenase to xanthine oxidase 
[12, 13]. Upon reoxygenation, a burst of superoxide radicals may be formed in certain cell types 
by the action of xanthine oxidase upon accumulated hypoxanthine and xanthine substrates [7]. 
 
In the presence of suitably chelated iron, a fraction of the superoxide generated by biological 
sources may participate in the superoxide driven Fenton reaction, in which hydroxyl radical 






 is a chelator anion rendering iron soluble at physiological pH. Nascent hydroxyl 
radicals, or perhaps intermediate oxo-iron complexes themselves [16, 17], can react with various 
proteins, nucleic acids or lipids in the cell [4, 18, 19], initiating chains of uncontrolled free 
radical reactions that may complicate circulatory shock, arterial thromboembolism, cardiac 
arrest, and other clinical entities. 
 
There are currently several methods under investigation to prevent or attenuate superoxide and 
iron mediated injury. The first is the use of antioxidant enzymes such as superoxide dismutase 
(SOD) and catalase which scavenge and break down superoxide and hydrogen peroxide, 
respectively [20, 21]. Alternatively, iron chelating compounds such as deferoxamine may inhibit 
superoxide-initiated injury, presumably by preventing the redox cycling of iron [22, 23]. Another 
attractive approach may be the use of xanthine oxidase inhibitors [2, 24, 25]. Best known among 
these inhibitors are the purine analogs, oxypurinol and allopurinol, which bind competitively to 
the purine binding site of the enzyme, displacing hypoxanthine and xanthine.  
 
However, another neglected approach to pharmacologic inhibition of O2

 production by xanthine 
oxidase exists. In 1988, Kelner et al. [26] re-examined the early work of McCord and Fridovich 
[27] suggesting that methylene blue can act as a willing electron acceptor for xanthine oxidase, 
an enzyme that allows for the anaerobic oxidation of purine substrates. They proposed that this 
readily available and already clinically used compound might inhibit the production of 
superoxide in postischemic tissues [26] by competing with molecular oxygen at the iron-sulfur 
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centers of xanthine oxidase. Intrigued by Kelner’s thoughts and observations, we have begun to 
study methylene blue as a possible inhibitor of O2

 production by xanthine oxidase.  
 
In this paper, we present an elaboration of Kelner’s original idea concerning the mechanism of 
action and pharmacology of methylene blue during oxidative stress. We propose that methylene 
blue (and perhaps other related compounds) may attentuate the pathophysiology of reperfusion 
injury by two methods: First, if given as a pretreatment (prior to ischemia), it may allow for the 
anaerobic breakdown of hypoxanthine and xanthine to uric acid and thus attenuate the 
accumulation of hypoxanthine during ischemia. Second, if given either before ischemia or just 
before reperfusion, methylene blue may help prevent superoxide formation, since it competes 
favorably with molecular oxygen for reduction by xanthine oxidase [28]. In this hypothetical 
role, methylene blue does not act as a classical xanthine oxidase inhibitor, because it does not 
slow the rate of oxidation of hypoxanthine or xanthine. Indeed, it appears to increase the rate of 
such reactions in some studies [28]. Instead, methylene blue acts an inhibitor of oxygen 
reduction, and may well function as such for other oxidases in addition to xanthine oxidase.  
 
Routine use of methylene blue as a tissue stain leaves little doubt as to its ability to penetrate 
intracellular as well as extracellular fluid compartments. Note however, that the doses required to 
achieve the desired therapeutic effect are insufficient to render an animal or patient comically 
blue in color (pseudocyanosis) and indeed are within the range currently recommended for use in 
human medicine.  
 
Biochemically, our working hypothesis is that methylene blue is reduced to the colorless leuko 
form, as a result of the action of xanthine oxidase.  In the presence of oxygen, the 
leukomethylene blue then auto-oxidizes back to ordinary methylene blue with the concurrent 
formation of hydrogen peroxide directly, rather than superoxide. The transfer of electrons in 
pairs to methylene blue, rather than singly to oxygen, thus short-circuits the formation of 




 does not occur, and 
even though hydrogen peroxide is formed, there is not sufficent Fe
2+
 to allow for either the 
formation of damaging amounts of HO by Fenton’s reaction or the formation of ferrous-ferric 
complexes capable of initiating lipid peroxidation in the absence of HO [16, 17]. The hydrogen 
peroxide that is formed is then readily detoxified in vivo by the action of catalase and 
peroxidases. 
 
Regarding the products of auto-oxidation of leukomethylene blue, there appear to be two schools 
of thought, one stating that leukomethylene blue auto-oxidizes to hydrogen peroxide [26, 29] and 
another stating that leukomethylene blue can auto-oxidze univalently to superoxide [27]. 
Accordingly, we were especially interested in exploring the major products of leukomethylene 
blue auto-oxidation. Significant univalent reduction of oxygen by leukomethylene blue to form 
superoxide would obviate the use of methylene blue to suppress superoxide formation.  
 
For these reasons, we gave serious consideration to the potential use of methylene blue as a drug 
to suppress superoxide formation by xanthine oxidase and performed a number of simple 
biochemical experiments to (1) explore the number of electrons transferred during methylene 
blue reduction, (2) determine if model iron-sulfur centers could reduce methylene blue, (3) 
 
4 
measure superoxide production during auto-oxidation of leukomethylene blue, and (4) test the 
ability of methylene blue to suppress one indicator of oxygen radical injury in a tissue model of 
ischemia and reperfusion. 
 
 
METHODS AND RESULTS 
 
Stoichiometry of methylene blue reduction 
 
To further explore the antioxidant potential of methylene blue in the laboratory, we first studied 
the stoichiometry of electron transfer from xanthine to methylene blue. Others have suggested 
that for each oxidation step, either from hypoxanthine to xanthine or from xanthine to uric acid, 
there are two electrons transferred to the enzyme [8, 30]. If, in turn, xanthine oxidase transfers 
two electrons to methylene blue in each oxidation step, we expect 1 mole of leukomethylene blue 
to be produced for each mole of xanthine oxidized to uric acid and 2 moles of leukomethylene 
blue for each mole of hypoxanthine oxidized completely to uric acid. 
 
To test this assertion, we performed some simple spectrophotometric studies. A reaction mixture 
of 0.05 units/ml of xanthine oxidase was added to a 1.5-mL quartz spectrophotometric cuvet 
containing 37.4 nmol of methylene blue, and 15 nmol of either xanthine or hypoxanthine in 
argon-saturated (anoxic) Tris-Ringer buffer* at pH 7.4. The reaction vessel was suffused with 
argon and covered to exclude oxygen. The conversion of methylene blue to leukomethylene blue 
was recorded as a decrease in the absorbance of the solution at 667 nm. Based on the extinction 






, our value), the amount of 
methylene blue reduced was calculated. Our measured coefficient is in good agreement with the 




) [31]. The results (Table 1) indicated that xanthine oxidase 
supplied with 15 nmol of xanthine reduced 14.6  0.3 nmol of methylene blue (mean  SEM) 
and 15 nmol of hypoxanthine reduced 29.1  0.4 nmol of methylene blue (N = 10).  
 
These observations confirm that the reduction of methylene blue is a 2-electron process as 
previously indicated by Blaedel and Meloche [32]. This observation is important, because if 
leukomethylene blue is a 2-electron reduction product of methylene blue, then it is reasonable to 
expect that two electrons might also be transferred to molecular oxygen when methylene blue 









* The Tris-Ringer buffer solution included 4.0 mM KCl, 100 mM NaCl, 2.0 mM CaCl2, 40 mM 
Tris, and 200 mg/dL glucose, pH 7.4. Tris was chosen as a buffer rather phosphate because of its 






Table 1. Methylene blue reduction by xanthine oxidase under anaerobic conditions.  







Reaction of model iron-sulfur centers with methylene blue 
 
The reduction of methylene blue by xanthine oxidase occurs in both the molybdenum free and 
deflavinated enzyme forms [33, 34]. Therefore, it has been suggested that the point of methylene 
blue reduction must be at the iron-sulfur center [26]. The native xanthine oxidase enzyme 
contains two iron-sulfur centers of the 2Fe-2S type [8, 35], having two iron atoms chelated by six 







Fig. 1. Cartoon-like sketch of xanthine oxidase, illustrating the proposed role of 
methylene blue (MB) as a parasitic electron acceptor. The enzyme consists of two 
subunits, each with purine binding sites, Mo
IV
, iron-sulfur (Fe-S) centers, and a flavin 
[8, 35-37]. The catalytic action is illustrated with molecular oxygen (left) and 
methylene blue (right) serving as electron acceptors. In the normal sequence on the 
left, electrons travel to the flavin to be transferred to oxygen, forming superoxide [36, 
37]. The authors propose that in the presence of methylene blue, on the right, the 
electrons are diverted to the dye at the iron-sulfur center. In this way, methylene blue 





To further explore this concept, we sought to determine if a reduced iron-sulfur center can, in 
fact, reduce methylene blue. In simple aqueous solutions, ferrous iron alone did not reduce 
methylene blue and neither did thiols. Hence, the juxtaposition of iron and sulfur atoms of the 
iron-sulfur center must be critical. To model a reduced iron-sulfur center, we utilized the chelate 
of Fe
2+
 and an excess of dimercaptosuccinic acid (DMSA) in dilute, anoxic (argon saturated) 
solutions. The combination of these reagents caused an evident interaction between the ferrous 
iron and the sulfur groups of DMSA, which formed a colored chelate that ranges from brown to 
pink, depending on the relative concentrations of the two compounds, and was not formed upon 
combination of ferrous iron with ordinary succinic acid. This model is less complex than the true 
structure of the iron-sulfur center, but it still includes an Fe
2+
 surrounded by at least four sulfurs 







Fig. 2. An idealized configuration of the DMSA-iron chelate. The Fe
2+
 is chelated by 
the four sulfhydryl groups of two dimercaptosuccinic acid molecules. This complex 
models the iron:sulfur ratio seen in the iron-sulfur centers of xanthine oxidase and 
appears to mimic the iron-sulfur center of xanthine oxidase in that it is capable of 
reducing methylene blue. 
 
 
These experiments used 50 nmol/mL of Fe
2+
 chelated in the presence of 800 nmol/mL of DMSA. 
At the above concentrations, the chelate formed was pink in color and exhibited an absorbance 
peak at 360 nm. DMSA (from Aldrich) and 50 nmol of FeSO4 were added to argon-saturated 
(anoxic) Tris-Ringer buffer (1.0 mL, pH 7.4), after which 15 nmol of methylene blue was added.  
 
In N = 6 trials, the absorbance of the methylene blue (667 nm) was seen to decrease after only 3 
min (Fig. 3). The cuvet was then reoxygenated by gently bubbling with 100% O2 to promote the 
auto-oxidation of leukomethylene blue with return of the original color. DMSA-only and Fe
2+
- 
only controls did not reduce methylene blue (N = 3). These simple experiments are consistent 
with the hypothesis that reduced iron-sulfur centers, similar to those in xanthine oxidase, can, in 











Fig. 3. Typical visible spectra illustrating methylene blue reduction in the presence of 
the model iron-sulfur (Fe-S) center. (1) A 6 M concentration of methylene blue (MB) 
showed characteristic absorbance peak at 667 nm. (2) After 3 min, the methylene blue 
absorbance peak was reduced anaerobically in the presence of the model Fe-S centers 
(50 M FeSO4 + 800 M DMSA). (3) When this mixture was reoxygenated, the 
leukomethylene blue auto-oxidized and the original blue color returned. (4) The 
spectrum of the chelate alone is included for comparison. Spectra were manually 
digitized for plotting. FeSO4 alone and DMSA alone did not reduce methylene blue 





Auto-oxidation of leukomethylene blue 
 
To more directly test the hypothesis that methylene blue auto-oxidation yields H2O2 rather than 
O2

, we compared auto-oxidation of Fe
2+
-citrate with that of leukomethylene blue. Ferrous-
citrate is expected to auto-oxidize via a single electron transfer, Fe
2+





) thus providing a positive control. Fe
2+
-citrate (500 M) was added to an O2 bubbled 
solution of pH 7.4 Tris buffer. To detect O2

, nitroblue tetrazolium (NBT, 500 M) was added at 
0, 15, 30, 45, 60, or 90 sec after Fe
2+
-citrate oxidation had begun and allowed to react for 3 min 
at room temperature. In the presence of O2

 NBT is reduced to a purple diformazan, which can 
be extracted into toluene and measured spectrophotometrically [38]. This approach was selected 
as an alternative to cytochrome-c reduction for the present application, because the leuko-dyes as 
well as O2

, are known to reduce cytochrome-c [27].  
 
In a similar fashion, methylene blue (250 M) was reduced to leukomethylene blue by addition 
of equimolar amounts of sodium hydrosulfite at pH 7.4. The solution was then reoxygenated 
until the blue color completely returned (approximately 10 sec), after which NBT was added at 
similar times as above. In some experiments, the NBT was added into the leukomethylene blue 
at time 0 and the solution then reoxygenated. Parallel control experiments were performed in the 
presence of 2 mg/mL (6000 units/ml) superoxide dismutase from Sigma (N = 3). 
 
The reduced NBT from the auto-oxidation experiments was then extracted into 3 vol. of toluene 
and read in a spectrophotometer (max = 595 nm) against a toluene blank. Based on the extinction 






), the concentration of 
reduced NBT was calculated by Beer’s Law. Results of such time course experiments comparing 
auto-oxidation of Fe
2+
-citrate and leukomethylene blue are shown in Fig. 4. 
 
The left panel of Fig. 4 illustrates the SOD inhibitable reduction of NBT following auto-
oxidation of Fe
2+
-citrate during the first 150 sec. The decrease in colored diformazan formation 
with later addition of NBT reflects the spontaneous dismutation of O2

 to H2O2. In comparison, 
the right panel of Fig. 4 shows negligible amounts of SOD inhibitable NBT reduction following 
auto-oxidation of leukomethylene blue during the first 150 sec. NBT reduction at time 0 is 
attributable to the direct action of leukomethylene blue in the absence of oxygen, which was not 
SOD inhibitable. These observations are consistent with the hypothesis that molecular oxygen 
reacting with leukomethylene blue in buffered, neutral aqueous solution is not reduced to 









Fig. 4. Left panel: Appearance of SOD inhibitable NBT reducing equivalents after 
auto-oxidation of 500 M Fe2+-citrate in pH 7.4 Tris buffer. Auto-oxidation began at 
time zero. NBT (500 M) was added at the times indicated, and reduced NBT was 
recovered by toluene extraction and measured spectrophotometrically. The NBT 
reducing equivalents detected decayed exponentially over time as would be expected for 
superoxide undergoing spontaneous dismutation. Addition of Sigma SOD (6000 
units/mL) completely quenched NBT reduction by this system. This experiment 
constitutes a positive control since auto-oxidation of ferrous iron chelates is well 
known to produce superoxide. Values are means  SEM for N = 3. Right panel: 
Appearance of NBT reducing equivalents after auto-oxidation of leukomethylene blue. 
This series of experiments was similar to the series in the left panel. Leukomethylene 
blue was produced by the addition of 250 M sodium hydrosulfite to an equimolar 
amount of methylene blue under anaerobic conditions. The solution was then bubbled 
with 100% oxygen to initiate auto-oxidation of leukomethylene blue. NBT (500 M) 
was added at the times indicated, and reduced NBT, recovered by toluene extraction, 
was measured spectrophotometrically. When NBT was added directly to 
leukomethylene blue, there was reduction of NBT before addition of oxygen that was 
not SOD inhibitable. There was no SOD inhibitable NBT reduction after oxidation. 





Inhibition of reoxygenation injury in tissue slices 
 
To test the ability of methylene blue to quench free radical formation in ischemia/reperfusion, we 
employed a previously described model of ischemia and reoxygenation [39, 40] in vitro, in 
which free floating liver or kidney slices were exposed to 60 min of ischemia in argon-saturated 
(anoxic) buffer before being treated with methylene blue at final concentrations of 0, 1, 2, 5, 10 
or 25 g/mL (mg/kg) 10 min prior to reoxygenation. The tissues were then reoxygenated in 
100% O2 saturated buffer for 60 min, after which the tissues and buffer were assayed, using the 
thiobarbituric acid reaction [41] for malondialdehyde-like materials (MDA-LM), which are 
indicators of free radical mediated lipid peroxidation. The results (Figs. 5 and 6) show that 
significant production of MDA-LM occurred at zero or low concentrations of methylene blue. 




Fig. 5. Postischemic MDA-LM production, an indicator of lipid peroxidation, in rat 
kidney slices in the presence of various concentrations of methylene blue. Methylene 
blue was added 10 min prior to reoxygenation of tissues that were ischemic for 1 hr 
total. Reoxygenation was with 100% oxygen gas. Mean productions of MDA-like 
materials measured by the thiobarbituric acid method are shown  SEM. An asterisk 
(*) indicates significance vs. untreated controls at  = 0.05 by Scheffe’s multiple 







Fig. 6. Postischemic MDA-LM production, an indicator of lipid peroxidation, in rat 
liver slices in the presence of various concentrations of methylene blue. Methylene blue 
was added 10 min prior to reoxygenation of tissues that were ischemic for 1 hr total. 
Reoxygenation was with 100% oxygen gas. Mean productions of MDA-like materials 
measured by the thiobarbituric acid method are shown  SEM. An asterisk (*) 
indicates significance vs. untreated controls at  = 0.05 by Scheffe’s multiple 
comparison est. Values are means  SEM for N = 6. 
 
Methylene blue alone did not inhibit the thiobarbituric acid reaction, as was determined by 
adding various methylene blue concentrations to MDA standards and observing no inhibition of 
reaction product formation. These data confirm those previously published [39] and suggest that 
clinically realistic doses (5 mg/kg) of methylene blue can protect against oxygen radical 







The foregoing simple experiments support the claim that methylene blue may well be an 
effective antioxidant in the setting of ischemia/reperfusion injury when administered in clinically 
realistic concentrations prior to the return of molecular oxygen. Methylene blue, together with 
other related compounds such as celestine blue, toluidine blue O, thionin, and azure A, which are 
also reduced to leuko forms by xanthine oxidase (unpublished observations) [42], may constitute 
a new class of antioxidant drugs that act by suppressing O2

 formation by tissue oxidases. In 
contrast to classical purine analog type xanthine oxidase inhibitors. these agents would not 
inhibit hypoxanthine and xanthine conversion to uric acid, but would selectively inhibit O2

 
formation by serving as competitive, alternative co-substrates. 
 
Such alternative electron acceptors seem to be characterized by their apparent ability to accept 
two electrons, rather than one electron, and, in turn, auto-oxidizing to form H2O2 directly rather 
than O2











The high affinity of methylene blue for the iron-sulfur center of xanthine oxidase [28] favors the 
former over the latter sequence, even in the presence of 100% O2 during reoxygenation. In this 
sense, we argue that methylene blue acts as a “parasitic” electron acceptor, shunting electron 
flow from the normal pathway within the enzyme to form leukomethylene blue at the level of the 
iron-sulfur centers (Fig. 1, right). The drug effectively short-circuits O2

 generation since the 
electron flow through the enzyme is preferentially routed to methylene blue at the iron-sulfur 
center rather than to molecular oxygen at the flavin centers. In turn, redox cycling of low 
molecular weight chelate iron in the superoxide driven Fenton reaction is avoided, because there 






Although earlier work by McCord and Fridovich [27] indicated that reduced methylene blue was 
capable of univalently reducing oxygen to superoxide, the detection method used (adenochrome 
formation) indicated that the rate of superoxide formation was relatively slow. The present 
results clearly indicate that the formation of hydrogen peroxide, rather than superoxide, is the 
dominant product of leukomethylene blue auto-oxidation, compared to ferrous citrate auto-
oxidation, in which abundant superoxide is formed. The end result, prevention of O2

 generation, 
is similar to the effect of SOD. However, unlike SOD, methylene blue, which is a low molecular 
weight, partially liposoluble agent, is unquestionably able to penetrate cells and tissues, in view 
of its use as a rapidly penetrating histological stain. These properties may make methylene blue 
an especially useful pharmacologic agent, which has already been proven safe at likely effective 
doses in human patients. 
 
Methylene blue is currently used in medicine for the treatment of cyanide poisoning, 
methemoglobinemia, nitrite poisoning, and urinary tract infections [43-47]. In a guinea pig 
model of nitrite toxicosis, 10 mg/kg of methylene blue protected against methemoglobinemia 
following a 50 mg/kg dose of NaNO2 [47]. As early as 1935, methylene blue was used as a 
treatment for urinary tuberculosis [44]. The treated human patients showed post-operative weight 
increase and relief of symptoms in 11 of 12 cases with unilateral renal tuberculosis. In the case of 
methemoglobinemia in the adult human, methylene blue is given as an injection of 50 mL of a 
1% solution. The dye then acts therapeutically to accelerate reductive processes in the cell. It is 
effective in cases of NADPH-methemoglobin reductase deficiency but not in cases of 
methemoglobinemia due to glucose-6-phosphate dehydrogenase deficiency [46, 48]. It is also a 
relatively non-toxic compound and can be used over a wide range of doses. In humans with 
cyanide poisoning, a 500 mg bolus is given, which corresponds to a dose of approximately 7 
mg/kg [49]. In the dog and rat, the LD50 values (median lethal dose) for i.v. methylene blue are 
50 and 1250 mg/kg, respectively. In monkeys, the lowest published toxic dose is 10 mg/kg [50].  
 
The action of methylene blue and similar drugs as parasitic electron acceptors opens up a variety 
of therapeutic possibilities. As a pretreatment, as in cases of aortic cross-clamping or organ 
transplantation, methylene blue might be given just prior to the ischemic period to provide a 
substrate for the anaerobic breakdown of hypoxanthine and xanthine. In conditions such as 
circulatory shock, arterial thromboembolism, or bowel torsion with strangulation, methylene 
blue could be given as a post-treatment (i.e. after the onset of ischemia) and still be effective, 
since the competition kinetics favor the reduction of methylene blue rather than molecular 
 
15 
oxygen [28]. The low-toxicity, effectiveness, and unique biochemistry of methylene blue and its 
congeners, may make such compounds valuable in the future study and treatment of tissue injury 
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